NON-OPIOID PAIN THERAPEUTICS COMPANY REGULONIX RAISES $2 MILLION IN SEED FUNDING LED BY UAVENTURE CAPITAL FUND

Regulonix, LLC, a University of Arizona biotechnology start-up company focused on developing non-opioid therapeutics to relieve chronic pain, today announced seed investment of $2 million. UAVenture Capital Fund, LLC, the Tucson-based early stage capital fund dedicated to commercializing University of Arizona (UA) technology, led the seed round, with participation from Tucson’s Desert Angels, one of the country’s leading angel investor groups.

Regulonix will use the proceeds to fund several preclinical development milestones of its internationally patented lead compounds, demonstrated in animal models to be non-addictive and more effective than morphine.  The company’s unique platform helps address a global pain management therapeutics market projected to reach $83B by 2024.

 

NON-OPIOID PAIN THERAPEUTICS COMPANY REGULONIX RAISES $2 MILLION IN SEED FUNDING LED BY UAVENTURE CAPITAL FUND